Bayer consensus stays cautious, DAX shares tick up on Supreme Court focus
23.06.2026 - 20:01:59 | ad-hoc-news.de
By Anna Wagner, Analysts & Consensus desk. Reviewed prior to publication on 2026-06-23, 20:01.
Bayer (DE000BAY0017) sits in the DAX with a complex risk profile that keeps analyst consensus cautious. On Xetra the shares trade modestly higher on Tuesday, as investors watch for a US Supreme Court move on the long-running glyphosate litigation according to Jefferies and local market commentary.MarketScreener Bayer overview
What analyst data shows
Consensus data compiled by MarketScreener indicates that Bayer carries a mixed recommendation profile, with a range from Sell to Buy, reflecting litigation and balance-sheet concerns.Finanzen.net overview of Bayer price targets In mid-June, Sadif Investment Analytics downgraded the stock to Sell, highlighting ongoing uncertainty around legal risks and profitability trends.
At the same time, AlphaValue/Baader Europe maintains a Buy rating on Bayer, signaling confidence in the group’s long-term cash generation and portfolio strength despite litigation overhang. Jefferies has reiterated that the Supreme Court decision on glyphosate is a central catalyst and is still pending, leaving valuation debates open between more cautious and more optimistic research houses.
Supreme Court and drug-price scrutiny
Jefferies recently underlined that the awaited US Supreme Court ruling on glyphosate-related cases remains one of the key event risks for Bayer, with potential implications for settlement structures and future cash outflows. German and international market reports note that the US legal environment, including class-action pathways, is a core reason for the wide dispersion of analyst views on the shares.
In parallel, US authorities have opened an investigation into German drug prices, and press reports have flagged a possible tariff angle, which adds an additional regulatory layer for Bayer’s pharmaceuticals arm according to dpa and Reuters-based summaries.Boersennews Bayer news summary This broader scrutiny feeds into analysts’ assumptions on margins and geopolitical risk premia.
All news and analysis on the Bayer shares
Further corporate releases, analyst reports and price data on Bayer can be found in the dedicated topic section and on the company’s Investor Relations site.
The products behind the stock
Bayer generates revenue across three main segments: Pharmaceuticals, Consumer Health and Crop Science. Flagship pharmaceutical products include cardiovascular therapies and oncology drugs, while in Crop Science the group sells seeds and crop-protection solutions to farmers worldwide.Bayer description of business segments
Where the Bayer shares trade today
The Bayer shares (DE000BAY0017) trade on 2026-06-23 at 18:10 on Xetra at 38.58 euros, according to real-time data reported by Tagesschau and exchange feeds.Tagesschau Bayer real-time quote
Key data on the Bayer shares
- Company: Bayer Aktiengesellschaft
- ISIN: DE000BAY0017
- WKN: BAY001
- Ticker: BAYN
- Trading venue: Xetra
- Price (as of 2026-06-23, 18:10): 38.58 EUR
- Market cap: around 38 billion EUR (as of 2026-06-23, based on Xetra price and latest share count)
- Sector / industry: Health Care / Pharmaceuticals & Crop Science
- Index membership: DAX, STOXX Europe 600, EURO STOXX 50
- Next earnings date: not officially scheduled
Disclaimer: This article provides factual information on the Bayer shares and does not contain investment advice or recommendations. All data are based on publicly available sources believed to be reliable at the time of publication.
